Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis

被引：55
|
作者：
Mildiner, Sorcha [1 ]
Malnick, Stephen [1 ]
机构：
[1] Kaplan Med Ctr, Rehovot, Israel
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 17期
关键词：
D O I：
10.1056/NEJMc1702076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1692 / 1693
页数：2
相关论文
共 50 条
  • [41] Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis
    Hauser, Stephen
    Kappos, Ludwig
    Montalban, Xavier
    Chognot, Cathy
    Pasquarelli, Noemi
    Singh, Varinder
    Incera, Elodie
    Wolinsky, Jerry
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 333 - 334
  • [42] Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report
    Puig-Casadevall, Marc
    Alvarez-Bravo, Gary
    Varela, Ana Quiroga
    Robles-Cedeno, Rene
    Cirera, Laura Sanchez
    Miguela, Albert
    Laguillo, Gemma
    Montalban, Xavier
    Hauser, Stephen L.
    Ramio-Torrenta, Lluis
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (10) : 3357 - 3361
  • [43] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Wu, J.
    Stavropoulos, A.
    Sanchez, Alvarez J.
    Diles, D.
    VALUE IN HEALTH, 2021, 24 : S161 - S161
  • [44] Psoriasis caused by ocrelizumab in two persons with primary progressive multiple sclerosis
    Jakob Brecl, Gregor
    Gabelic, Tereza
    Ruska, Berislav
    Horvat Ledinek, Alenka
    Habek, Mario
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (09) : E322 - E324
  • [45] Real world experience with ocrelizumab in patients with primary progressive multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 302
  • [46] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Liu, C.
    Marcelli, G.
    Alvarez, Sanchez J.
    Overell, J.
    VALUE IN HEALTH, 2020, 23 : S632 - S633
  • [47] Prodrome in relapsing-remitting and primary progressive multiple sclerosis
    Wijnands, J. M. A.
    Zhu, F.
    Kingwell, E.
    Zhao, Y.
    Evans, C.
    Fisk, J. D.
    Marrie, R. A.
    Tremlett, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (07) : 1032 - 1036
  • [48] Initial real-life experience with ocrelizumab in patients with relapsing-remitting and primary progressive multiple sclerosis in Salzburg, Austria
    Feige, J.
    Moser, T.
    Nagy, Z.
    Otto, F.
    Wipfler, P.
    Trinka, E.
    Sellner, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 489 - 489
  • [49] Progressive multifocal encephalopathy in the first patient with relapsing-remitting multiple sclerosis treated with ocrelizumab
    Puig Casadevall, M.
    Alvarez Bravo, G.
    Coll-Martinez, C.
    Quiroga-Varela, A.
    Robles-Cedeno, R.
    Gonzalez del Rio, M.
    Salavedra-Pont, J.
    Miguela, A.
    Gich, J.
    Ramio-Torrenta, L.
    Boix-Lago, A.
    Laguillo-Sala, G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 679 - 680
  • [50] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Benjamin Turner
    Bruce A. C. Cree
    Ludwig Kappos
    Xavier Montalban
    Caroline Papeix
    Jerry S. Wolinsky
    Regine Buffels
    Damian Fiore
    Hideki Garren
    Jian Han
    Stephen L. Hauser
    Journal of Neurology, 2019, 266 : 1182 - 1193
12345